Phase 2 Bladder Cancer Trial, Recruiting NCT07232602 Sponsor: Merck Sharp & Dohme LLC Condition: Bladder Cancer
Back to Bladder Cancer

Phase 2 Bladder Cancer Trial, Recruiting

NCT07232602
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with bladder or urinary tract cancer (called urothelial carcinoma) that has either spread to nearby areas and cannot be removed by surgery, or has spread to other parts of the body
  • You are able to provide a tumor tissue sample, either one taken recently or one stored from a previous biopsy
  • You have not yet received any systemic (whole-body) treatment, such as chemotherapy, for your advanced or metastatic cancer
  • If you have HIV, it is well controlled with medication
  • If you have hepatitis B, you have been on antiviral treatment for at least 4 weeks and the virus is not detectable in your blood before joining the trial
  • If you have a history of hepatitis C, the virus is not detectable in your blood before joining the trial

Who may not be able to join:

  • You have a history of serious dry eye syndrome, serious eyelid gland disease, or a corneal (eye surface) condition that affects healing
  • You currently have an active eye infection or open sore on the surface of your eye
  • You have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) that requires immune-suppressing medication, or you have a history of these conditions or chronic diarrhea
  • You have had serious, uncontrolled heart or stroke-related problems within the past 6 months
  • You have diabetes that is not well controlled
  • You have a build-up of fluid around your lungs, abdomen, or heart that is causing symptoms or needs to be drained regularly
  • You have an autoimmune disease (where the immune system attacks the body) that has needed medical treatment in the past 2 years
  • You have another cancer that is growing or has needed active treatment within the past 2 years
  • You have cancer that has spread to your brain or the lining around your brain or spinal cord
  • You have a history of lung inflammation (pneumonitis) or scarring lung disease that required steroid treatment, or you currently have this condition
  • You have an active infection that is being treated with systemic (whole-body) medication
  • You have HIV along with a history of a condition called Kaposi's sarcoma or Multicentric Castleman's Disease
  • You have both hepatitis B and hepatitis C infections at the same time
  • You have previously had a stem cell or solid organ transplant (such as a kidney or liver transplant)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 February 2026
Est. completion
8 July 2031

Where this trial is recruiting

🇨🇱 Chile 🇫🇷 France 🇮🇱 Israel 🇳🇱 Netherlands 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of Participants Who Experience an Adverse Event (AE); Number of Participants Who Experience a Dose Limiting Toxicity (DLT); Number of Participants Who Discontinue Study Treatment Due to an AE; Objective Response Rate (ORR) as Assessed by Investigator

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov